 |
|
A Study on the Efficacy and Safety of Rivaroxaban in Urologic Cancer-Associated Venous Thromboembolism
Jang Ho Lee, Dalsan You, Sang-Do Lee, Yeon-Mok Oh, Jae Seung Lee
Korean J Urol Oncol. 2019;17(3):178-185. Published online 2019 Dec 27 DOI: https://doi.org/10.22465/kjuo.2019.17.3.178
|
|
Citations to this article as recorded by
 Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer
Anne Gulbech Ording, Mette Søgaard, Flemming Skjøth, Erik Lerkevang Grove, Gregory Y.H. Lip, Torben Bjerregaard Larsen, Peter Brønnum Nielsen
Research and Practice in Thrombosis and Haemostasi.2022; 6(1): e12629. CrossRef The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis
Mouhand F. H. Mohamed, Mohamad Nabil ElShafei, Mohamed Badie Ahmed, Lina O. Abdalla, Israa Ahmed, Abdel-Naser Elzouki, Mohammed ibn-mas’ud Danjuma
Clinical and Applied Thrombosis/Hemostasis.2021;[Epub] CrossRef
|